Hereditary Angioedema Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Hereditary Angioedema Epidemiology Forecast Report Coverage

Expert Market Research's “Hereditary Angioedema Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of hereditary angioedema. It projects the future incidence and prevalence rates of hereditary angioedema cases across various populations. The study covers age, gender, and type as major determinants of the hereditary angioedema population. The report highlights patterns in the prevalence of hereditary angioedema over time and projects future trends based on multiple variables.

Hereditary Angioedema Understanding: Disease Overview

Hereditary angioedema is a rare genetic disorder characterized by recurrent episodes of nonpruritic, nonpitting swelling affecting the skin, gastrointestinal tract, and airway. It is primarily caused by deficiency or dysfunction of C1 esterase inhibitor, leading to excessive bradykinin production and increased vascular permeability. HAE is typically classified into Type I, Type II, and forms with normal C1 inhibitor levels. Attacks may be spontaneous or triggered by stress, trauma, or hormonal changes. Laryngeal involvement can be life-threatening, making early diagnosis and prophylactic management critical.

Hereditary Angioedema Epidemiology Perspective

The hereditary angioedema epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the hereditary angioedema epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for hereditary angioedema and their trends. The hereditary angioedema detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• HAE affects approximately 1-2 individuals per 100,000 people worldwide, classifying it as a rare disease.
• Type I HAE accounts for approximately 85% of cases, while type II comprises the remaining 15%.
• Onset of symptoms typically occurs in childhood or adolescence, but diagnosis is often delayed by 5-10 years due to misidentification.
• HAE impacts both males and females equally, although symptom severity may vary among individuals.
• Recurrent swelling episodes can affect skin, extremities, face, gastrointestinal tract, and airways, posing a risk of life-threatening laryngeal attacks.

Read more about this report - Request a Free Sample

Country-wise Hereditary Angioedema Epidemiology Segment

The hereditary angioedema epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

Hereditary Angioedema (HAE) is a rare but clinically significant genetic disorder, impacting both healthcare systems and patient quality of life. In the United States, approximately 6,000-8,000 individuals are estimated to be living with HAE, with type I representing about 85% of cases. Additionally, in the United Kingdom, 1152 patients have been identified, indicating a minimum prevalence of 1 in 59,000, with 92% having type I HAE and a slight female predominance. These data highlight the need for timely diagnosis, improved patient education, and optimized management strategies to reduce disease burden.

Hereditary Angioedema: Treatment Overview

Treatment for hereditary angioedema includes on-demand therapy for acute attacks and long-term prophylaxis to prevent recurrence. Acute episodes are managed with C1 esterase inhibitor concentrates, bradykinin B2 receptor antagonists, or kallikrein inhibitors. Prophylactic options include subcutaneous or intravenous C1 inhibitor replacement and monoclonal antibodies targeting plasma kallikrein. Recent therapeutic advances have improved convenience, safety, and attack prevention rates. Treatment selection depends on attack frequency, severity, and patient preference. Ongoing pipeline developments focus on oral kallikrein inhibitors and gene-targeted therapies to enhance long-term disease control.

Key Questions Answered

• What are the key findings of hereditary angioedema epidemiology in the 8 major markets?
• What will be the total number of patients with hereditary angioedema across the 8 major markets during the forecast period?
• What was the country-wise hereditary angioedema epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of cases of hereditary angioedema during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of hereditary angioedema during the forecast period of 2026-2035?
• What are the currently available treatments for hereditary angioedema?
• What are the disease risks, signs, symptoms, and unmet needs of hereditary angioedema?

Scope of the Hereditary Angioedema Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of hereditary angioedema based on several factors.
• Hereditary Angioedema Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The hereditary angioedema report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

Related Reports

Hereditary Angioedema Therapeutic Market

Hereditary Angioedema Drug Pipeline Analysis